Lv1
60 积分 2023-10-31 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
3天前
已完结
Profiling Interactions Between Bicyclol and SLC/ABC Transporters: Advancing Clinical Safety and Efficacy in Combination Therapy
11天前
已完结
Integrated mutational landscape analysis of endometrial stromal sarcoma
19天前
已完结
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
1个月前
已完结
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis
1个月前
已完结
基于倾向性评分匹配的肺腺癌二线化疗联合贝伐珠单抗或免疫检查点抑制剂的回顾性研究
2个月前
已完结
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
2个月前
已完结
Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma
2个月前
已完结
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
2个月前
已完结
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
2个月前
已完结
皖公网安备34019202002308
